Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer

作者：Tobias Balint^*; Halaszlaki Csaba; Balla Bernadett; Kosa Janos P; Arvai Kristof; Horvath Peter; Takacs Istvan; Nagy Zsolt; Horvath Evelin; Horanyi Janos; Jaray Balazs; Szekely Eszter; Szekely Tamas; Gyori Gabriella; Putz Zsuzsanna; Dank Magdolna; Valkusz Zsuzsanna; Vasas Bela; Ivanyi Bela; Lakatos Peter

来源：Pathology and Oncology Research, 2016, 22(1): 27-33.

DOI：10.1007/s12253-015-9969-9

• Papillary thyroid cancer
• BRAF
• RAS
• RET/PTC
• Mutation

The incidence of thyroid cancers is increasing worldwide. Some somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene translocations (RET/PTC, PAX8/PPAR-gamma) have been associated with the development of thyroid cancer. In our study, we analyzed these genetic alterations in 394 thyroid tissue samples (197 papillary carcinomas and 197 healthy). The somatic mutations and translocations were detected by Light Cycler melting method and Real-Time Polymerase Chain Reaction techniques, respectively. In tumorous samples, 86 BRAF (44.2 %), 5 NRAS (3.1 %), 2 HRAS (1.0 %) and 1 KRAS (0.5 %) mutations were found, as well as 9 RET/PTC1 (4.6 %) and 1 RET/PTC3 (0.5 %) translocations. No genetic alteration was seen in the non tumorous control thyroid tissues. No correlation was detected between the genetic variants and the pathological subtypes of papillary cancer as well as the severity of the disease. Our results are only partly concordant with the data found in the literature.

• 出版日期2016-1